JP7667742B2 - Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法 - Google Patents

Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法 Download PDF

Info

Publication number
JP7667742B2
JP7667742B2 JP2021559100A JP2021559100A JP7667742B2 JP 7667742 B2 JP7667742 B2 JP 7667742B2 JP 2021559100 A JP2021559100 A JP 2021559100A JP 2021559100 A JP2021559100 A JP 2021559100A JP 7667742 B2 JP7667742 B2 JP 7667742B2
Authority
JP
Japan
Prior art keywords
cancer
akt
compound
methyl
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526979A5 (cg-RX-API-DMAC7.html
JP2022526979A (ja
Inventor
グレイ,ナサナエル
ユ,インチュル
ジャン,ティンフー
フィッシャー,エリック
ドノヴァン,キャサリン
エリクソン,エミリー
トケル,アレックス
Original Assignee
ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド
ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド, ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド filed Critical ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド
Publication of JP2022526979A publication Critical patent/JP2022526979A/ja
Publication of JP2022526979A5 publication Critical patent/JP2022526979A5/ja
Application granted granted Critical
Publication of JP7667742B2 publication Critical patent/JP7667742B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021559100A 2019-04-09 2020-04-08 Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法 Active JP7667742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831267P 2019-04-09 2019-04-09
US62/831,267 2019-04-09
PCT/US2020/027236 WO2020210337A1 (en) 2019-04-09 2020-04-08 Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use

Publications (3)

Publication Number Publication Date
JP2022526979A JP2022526979A (ja) 2022-05-27
JP2022526979A5 JP2022526979A5 (cg-RX-API-DMAC7.html) 2023-04-14
JP7667742B2 true JP7667742B2 (ja) 2025-04-23

Family

ID=72750645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559100A Active JP7667742B2 (ja) 2019-04-09 2020-04-08 Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法

Country Status (7)

Country Link
US (1) US12642857B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952871A4 (cg-RX-API-DMAC7.html)
JP (1) JP7667742B2 (cg-RX-API-DMAC7.html)
CN (1) CN113645972A (cg-RX-API-DMAC7.html)
AU (1) AU2020270908B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020210337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478534B (zh) * 2020-10-24 2025-08-05 杭州中美华东制药有限公司 具有抗肿瘤活性的嵌合分子及其制备方法和应用
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
CN120157686A (zh) * 2023-12-14 2025-06-17 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
IL325256A (en) 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
JP2021515013A (ja) * 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLAKE F. J. et al,Discovery and Preclinical Pharmacology of aSelective ATP Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors,J. Med. Chem,2012年,vol 55, no 18,pp.8110-8127
OTTIS P. et al.,Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy,ACS Chem. Biol.,2017年,vol 12, no 4,pp.892-898

Also Published As

Publication number Publication date
EP3952871A4 (en) 2023-06-07
US20220226481A1 (en) 2022-07-21
US12642857B2 (en) 2026-06-02
CN113645972A (zh) 2021-11-12
CA3134491A1 (en) 2020-10-15
AU2020270908A1 (en) 2021-09-16
AU2020270908B2 (en) 2025-09-25
WO2020210337A1 (en) 2020-10-15
JP2022526979A (ja) 2022-05-27
EP3952871A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
EP3890736A1 (en) Small molecule degraders of helios and methods of use
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
EP3813829A1 (en) Ligands to cereblon (crbn)
US20230158157A1 (en) Potent and selective degraders of alk
US12569563B2 (en) Selective HDAC6 degraders and methods of use thereof
JP7626721B2 (ja) 小分子標的ブロモ/アセチルタンパク質およびその使用
WO2020006262A1 (en) New crbn modulators
US20220401564A1 (en) Selective histone deacetylase (hdac) degraders and methods of use thereof
US20220387604A1 (en) Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof
AU2020270908B2 (en) Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use
WO2023283606A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof
WO2022235565A1 (en) Class iia histone deacetylase (hdac) degrader ligands and methods of use thereof
CA3233083A1 (en) Small molecules for dot1l degradation and uses thereof
WO2022140554A1 (en) Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof
US20240374737A1 (en) Erk5 degraders and uses thereof
AU2021297778A1 (en) Compounds for targeted degradation of interleukin-2-inducible T-cell kinase and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250411

R150 Certificate of patent or registration of utility model

Ref document number: 7667742

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150